Lucas G. Hill, Pharm.D., FCCP

National
American College of Clinical Pharmacy: Fellow (2023)
American College of Clinical Pharmacy: New Educator Award (2021)
American College of Clinical Pharmacy Ambulatory Care PRN: Outstanding Paper of the Year (2021)
Journal of the American Pharmacists Association: Outstanding Peer Reviewer (2021)
American Pharmacists Association: Generation Rx Award of Excellence (2020)
American College of Clinical Pharmacy Ambulatory Care PRN: Outstanding Paper of the Year (2019)
Journal of the American Pharmacists Association: Outstanding Peer Reviewer (2019)
American Society of Health-System Pharmacists: CEO’s Award for Courageous Service (2018)
Phi Lambda Sigma Pharmacy Leadership Society Inductee (2017)

Regional
Austin Under 40 Awards: Finalist in Medicine & Healthcare (2021)
Austin Under 40 Awards: Finalist in Medicine & Healthcare (2020)
Texas Pharmacy Association: Generation Rx Champion Award (2018)

Local
UT College of Pharmacy: 10 Most Impactful Faculty (2022)
UT College of Pharmacy: Outstanding Faculty Advisor (2019)
UT School of Undergraduate Studies: Distinguished University Lecturer (2018)
UT College of Pharmacy: 10 Most Impactful Faculty (2018)
UT College of Pharmacy: William Arlyn Kloesel Outstanding Preceptor (2017)
UT College of Pharmacy: ATW Regional Outstanding Preceptor (2017)
UT College of Pharmacy: IPPE Outstanding Preceptor (2017)

Fellowships
Bergen Brunswig Corporation Centennial Fellowship (2021–Present)
Alumni Centennial Endowed Fellowship Advisor (2019–2020)
Alumni Centennial Endowed Fellowship Preceptor (2017–2018)

Trainees
Claire Zagorski: UT WCAAR Bruce/Jones Fellowship in Addiction Biology (2023)
Amber Tran: AMERSA Growing a Diverse Workforce Award (2023)
Lindsey Loera: ACCP Research Fellowship Best Poster (2021)
Mandy Renfro: USPHS Public Health Excellence Award – Top Recipient (2020)
Lindsey Loera: USPHS Public Health Excellence Award (2019)
Lubna Mazin: USPHS Public Health Excellence Award (2018)
Andrea Laguado: USPHS Public Health Excellence Award (2017)
Andrea Laguado: TPA Generation Rx Champion Award (2017)

Principal Investigator (PI)

Empowering clinicians to prevent opioid-related harms and treat opioid use disorder: An academic detailing intervention for prescribers in Austin, Texas ($250,000)

• Sponsor: U.S. Substance Abuse and Mental Health Services Administration / City of Austin
• Funding Period: 09/30/2023–09/29/2024

Texas Targeted Opioid Response – PhARM Program special projects ($34,045,430)

• Sponsor: U.S. Substance Abuse and Mental Health Services Administration / Texas Health & Human Services Commission
• Funding Period: 5/1/2019–8/31/2024

SHIFTovation Award – Operation Naloxone ($44,000)

• Sponsor: UT University Health Services / UT Counseling and Mental Health Center
• Funding Period: 2/7/2020–08/31/2023

Center for Health Statistics – Drug dashboard enhancement ($102,500)

• Sponsor: U.S. Substance Abuse and Mental Health Services Administration / Texas Department of State Health Services
• Funding Period: 4/1/2021–8/31/2022

Texas Targeted Opioid Response – Operation Naloxone ($2,587,149)

• Sponsor: U.S. Substance Abuse and Mental Health Services Administration / Texas Health & Human Services Commission
• Funding Period: 7/1/2017–4/30/2019

Subaward PI

Creation of a multi-stakeholder practice guideline to improve access to medications for opioid use disorder in community pharmacies ($572,278)

• PI: Tyler Varisco, University of Houston
• Sponsor: Foundation for Opioid Response Efforts
• Funding Period: 4/1/2023–3/31/2025
• Subaward Amount: $28,872

A statewide needs assessment to identify opportunities to improve access to medications for opioid use disorder through mobile service provision ($162,579)

• PI: Jennifer Sharpe Potter, UT Health San Antonio
• Sponsor: U.S. Substance Abuse and Mental Health Services Administration via Texas Health & Human Services Commission
• Funding Period: 6/1/2022–8/31/2022
• Subaward Amount: $30,000

Co-Investigator

Preparing health professions learners for dual identity development using the interprofessional socialization framework ($4,000)

• PI: Veronica Young, UT Center for Health Interprofessional Practice and Education
• Sponsor: UT Center for Teaching and Learning Teaching Innovation Grants
• Funding Period: Summer 2022

Evaluation of naloxone counseling provided by community pharmacists ($3,995)

• PI: Kirk Evoy, UT College of Pharmacy
• Sponsor: UT Health San Antonio Center for Community Service Learning
• Funding Period: 2019­–2020

Operation Naloxone – Community overdose prevention training ($28,000)

• PI: Kirk Evoy, UT College of Pharmacy
• Sponsor: UT Health San Antonio Center for Community Service Learning
• Funding Period: 2018–2019

Naloxone training for the student faculty collaborative practice at UT Health San Antonio ($1,225)

• PI: Kirk Evoy, UT College of Pharmacy
• Sponsor: UT Health San Antonio Center for Community Service Learning
• Funding Period: 2018–2019

Operation Naloxone – Interprofessional overdose prevention service learning expansion ($3,344)

• PI: Kirk Evoy, UT College of Pharmacy
• Sponsor: UT Health San Antonio Center for Community Service Learning
• Funding Period: 2018–2019

Operation Naloxone – Interprofessional overdose prevention service learning ($4,000)

• PI: Kirk Evoy, UT College of Pharmacy
• Sponsor: UT Health San Antonio Center for Community Service Learning
• Funding Period: 2017–2018

Consultant

• U.S. Department of Justice: Civil Rights Unit, 2023–Present
• American Pharmacists Association: Buprenorphine Access Study, 2021–Present
• Foundation for Opioid Response Efforts: Pharmacy Program Advisory Committee, 2022
• UT Center for Health Communication: Texas Prescription Monitoring Program, 2017–2022
• American Academy of Addiction Psychiatry: Opioid Response Network, 2019–2021
• Hazelden Betty Ford Foundation: Innovation in Medical Education on Addiction, 2021
• Hikma Specialty USA, Inc.: Opioid Antagonist Community Advisory Board, 2020
• American Academy of Addiction Psychiatry: Clinical Skills for Healthcare Providers, 2019–2020
• The University of Texas at El Paso: Opioid Overdose Prevention Program, 2019

Selected Television & Radio Interviews
CNN Newsroom: FDA approves overdose treatment Narcan for over-the-counter use
KXAN Austin: Operation Naloxone – UT Austin library offering free doses of naloxone
KXAN Austin: Fentanyl overdoses dropped in 4 states. These solutions are helping.
KXAN Austin: Texas Longhorns linebacker Jake Ehlinger died of accidental overdose, family says
KCRW Los Angeles: Can you OD from touching fentanyl? How that myth gained a foothold among first responders.
FOX 7 Austin: CDC report ­– Drug overdose deaths hit record high in 2020
Texas Public Radio: Drug overdoses spiked during the pandemic. What’s fueling the surge?
CBS Austin: Texas AG’s office launches website to educate, prevent opioid misuse
CBS Austin: Austin billionaire named in new court filing for trying to shift blame for opioid addiction
KCBS San Francisco: Preventing overdose deaths on campus
NPR All Things Considered: On college campuses, making overdose medication readily available
Spectrum News Austin: Lone star crisis – the opioid epidemic
Spectrum News Austin: Capital Tonight – Trump unveils opioid plan
KXAN Austin: Advocates for painkiller addicts want society to meet them halfway
Spectrum News Austin: In Focus – The medication used to treat overdoses
NPR Marketplace: Overdose prevention on campus

Selected Print Interviews
Alcoholism & Drug Abuse Weekly: Stocking buprenorphine – The latest hitch in the MOUD field
TIME: Over-the-counter Narcan is a great first step, but there's still work to be done
Alcoholism & Drug Abuse Weekly: Is extra naloxone needed for overdose reversal in the fentanyl era?
Substance: Walmart is rejecting prescriptions and screwing over patients with addiction
TIME: Fewer than half of U.S. pharmacies carry one of the most effective drugs for opioid abuse
The Atlantic: An anti-overdose drug is getting stronger. Maybe that’s a bad thing?
VICE News: No, border patrol doesn’t need to be protected from fentanyl
Washington Post: A myth that lingers on – Casual contact with fentanyl causes overdoses
Popular Science: The CDC says more prescriptions of overdose reversal drug naloxone are needed
Pharmacy Today: Fentanyl-related deaths spike, but pharmacists can reduce associated harm
Pharmacy Times: Pharmacists role in providing naloxone is expanding
Austin American-Statesman: “We are not immune” – how the opioid crisis is hitting Central Texas
Drug Topics: Four ways pharmacists are fighting opioid abuse
Houston Chronicle: Texas college students, fearing opioid deaths, teach each other to reverse overdoses
Alcalde: How Texas is trying to stay ahead of the opioid epidemic
The Daily Texan: Operation Naloxone given grant to service opioid addiction
The Daily Texan: College of Pharmacy combats opioid overdoses with campus campaign

McCullough HP, Kane H, Duncan Cance J, Tatum C, Loera LJ, Kmetz L, *Hill LG. (2025). Wound care practices among people who inject drugs in Austin, Texas. Subst Use Addctn J. DOI: 10.1177/29767342251334203. 

*Hill LG. (2025). Redefining opioid stewardship. J Am Coll Clin Pharm. 8:168-170. DOI: 10.1002/jac5.70002.

Loera LJ, Lines J, Mayberry S, Hilzendager S, Ferguson A, *Hill LG. (2025). Over-the-counter naloxone and non-prescription syringe availability in community pharmacies. JAMA Netw Open. 8(2):e2458095. DOI: 10.1001/jamanetworkopen.2024.58095.

*Varisco TJ, Fish H, Bolin J, Dadiomov D, Hill LG, Essien E, Wanat MA, Ginsburg D, Waggener J, Thornton D. (2024). The pharmacy access to resources and medication for opioid use disorder (PhARM-OUD) guideline: A joint consensus practice guideline from the National Association of Boards of Pharmacy and the National Community Pharmacists Association. DOI: 10.52713/PhARM-OUD.

*Russell E, Hawk M, Neale J, Bennet A, Davis C, Hill LG, Winograd R, Kestner L, Lieberman A, Bell A, Santamour T, Murray S, Schneider KE, Walley AY, Jones TS. (2024). A call for compassionate overdose response as the standard of care. Int J Drug Policy. 133:104587. DOI: 10.1016/j.drugpo.2024.104587.

*Varisco TJ, Fish H, Bolin J, Dadiomov D, Hill LG, Essien E, Wanat MA, Ginsburg D, Waggener J, Yazdanfard S, Song J, Chi W, Thornton D. (2024). Protocol for the development of a consensus practice guideline to address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy. Arch Pub Health. 82(1):58. DOI: 10.1186/s13690-024-01287-4.

Light AE, Green TC, Freeman PR, Burns AL, Sanaty Zadeh P, *Hill LG. (2024). Relationships between stigma, risk tolerance, and buprenorphine dispensing intentions among community-based pharmacists: Results from a national sample. Subst Use Addctn J. DOI: 10.1177/29767342231215178.

Jarrett JB, Bratberg JP, Burns AL, Cochran G, DiPaula BA, Dopp AL, Elmes A, Green TC, Hill LG, Homsted F, Hsia SL, Matthews ML, Ghitza UE, Wu L, *Bart G. (2023). Research priorities for expansion of opioid use disorder treatment in the community pharmacy. Subst Abus. 44(4):264-276. DOI: 10.1177/08897077231203849.

Zagorski CM, Hosey R, Moraff C, Ferguson A, Figgatt M, Aronowitz S, Stahl N, Hill LG, McElligott Z, *Dasgupta N. (2023). Reducing the harms of xylazine: Clinical approaches, research deficits, and public health context. Harm Reduct J. 20:141. DOI: 10.1186/s12954-023-00879-7.

Zalmai R, *Hill LG, Loera LJ, Mosgrove Q, Brown CM. (2023). Community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder. J Am Pharm Assoc. 63(5):1558-1565. DOI: 10.1016/j.japh.2023.06.010.

*Ostrach B, Hill LG, Carpenter D, Pollini R. (2023). Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility. J Am Pharm Assoc. 63(4):1044-1048. DOI: 10.1016/j.japh.2023.04.029.

*Varisco TJ, Wanat M, Hill LG, Thornton D. (2023). The impact of the Mainstreaming Addiction Treatment Act and associated legislative action on pharmacy practice. J Am Pharm Assoc. 63(4):1039-1043. DOI: 10.1016/j.japh.2023.04.016.

Murchison ML, Loera LJ, *Hill LG. (2023). Medications for opioid use disorder in professional recovery programs in the United States: Policies and recommendation patterns. Ment Health Clin. 13(3):163-164. DOI: 10.9740/mhc.2023.06.163.

*Chatterjee A, Bannister M, Hill LG, Davis CS. (2023). Prescribing syringes to people who inject drugs: Advancing harm reduction in primary care. J Gen Intern Med. 38(8):1980-1983. DOI: 10.1007/s11606-023-08183-7.

*Claborn KR, Samora J, McCormick K, Whittfield Q, Courtois F, Lozada K, Sledge D, Burwell A, Chavez S, Bailey J, Bailey C, Pederson C, Zagorski C, Hill LG, Conway F, Steiker LH, Cance J, Potter J. (2023). “We do it ourselves”: Strengths and opportunities for improving the practice of harm reduction. Harm Reduct J. 20(1):70. DOI: 10.1186/s12954-023-00809-7.

Loera LJ, *Hill LG, Evoy KE, Reveles KR. (2023). Research and scholarly methods: Audit studies. J Am Coll Clin Pharm. 6(5):521-527. DOI: 10.1002/jac5.1782.

Britton TR, Clague MR, Zagorski CM, Hill LG, *Loera LJ. (2023). A wound care and immunization needs assessment for participants of a mobile syringe services program in Austin, Texas. J Am Pharm Assoc. 63(1):361-365. DOI: 10.1016/j.japh.2022.10.018.

Cance JD, Bingaman A, Kane H, Hairgrove S, Torrez SB, Buck A, Zagorski CM, Loera LJ, *Hill LG. (2023). A qualitative exploration of unintentional vs. intentional exposure to fentanyl among people who use drugs in Austin, Texas. J Am Pharm Assoc. 63(1):317-323. DOI: 10.1016/j.japh.2022.10.005.

*Hill LG, Light AE, Green TC, Burns AL, Sanaty Zadeh P, Freeman PR. (2023). Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists. J Am Pharm Assoc. 63(1):317-323. DOI: 10.1016/j.japh.2022.08.017.

Loera LJ, *Hill LG, Zagorski CM, Jermain ML, Tirado CF. (2023). Description and evaluation of a pilot advanced pharmacy practice experience in addiction medicine. Am J Pharm Educ. 87(1):8926. DOI: 10.5688/ajpe8926.

Lai RK, Friedson KE, Reveles KR, Bhakta K, Gonzales G, Hill LG, *Evoy KE. (2022). Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review. J Am Pharm Assoc. 62(6):1725-1740. DOI: 10.1016/j.japh.2022.07.008.

*Hill LG, Loera LJ, Torrez SB, Puzantian T, Evoy KE, Ventricelli DJ, Eukel H, Peckham AM, Chen C, Ganetsky V, Yeung M, Zagorski CM, Reveles KR. (2022). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 237:109518. DOI: 10.1016/j.drugalcdep.2022.109518.

Gugala E, Briggs O, Moczygemba LR, Brown CM, *Hill LG. (2022). Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice. Subst Abus. 43(1):972-987. DOI: 10.1080/08897077.2022.2060423.

White KM, *Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ. (2022). Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review. Subst Abus. 43(1):749-755. DOI: 10.1080/08897077.2021.2010161.

*Hill LG, Zagorski CM, Loera LJ. (2022). Increasingly powerful opioid antagonists are not necessary. Int J Drug Policy. 99:103457. DOI: 10.1016/j.drugpo.2021.103457.

*Evoy KE, Hill LG, Davis CS. (2021). Reply to letter to the editor regarding article: “Considering the potential benefits of over-the-counter naloxone”. Integr Pharm Res Pract. 10;77-78. DOI: 10.2147/IPRP.S327403.

*Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. (2021). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 116(6):1505-1511. DOI: 10.1111/ADD.15314.

*Bottner R, Weems J, Hill LG, Ziebell C, Long S, Young S, Sasser M, Ferguson A, Tirado C. (2021). Addiction treatment networks cannot withstand acute crises: Lessons from Winter Storm Uri in Texas. NAM Perspectives. DOI: 10.31478/202103c.

*Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH. (2021). Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic. Am J Health Syst Pharm. 78(7):612-618. DOI: 10.1093/ajhp/zxab003.

*Evoy KE, Hill LG, Davis CS. (2021). Considering the potential benefits of over-the-counter naloxone. Integr Pharm Res Pract. 10:13-21. DOI: 10.2147/iprp.S244709.

*Coon SA, Hill LG, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, Tran TH, McFee Winans AR, Bratberg JP. (2020). Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks for the American College of Clinical Pharmacy. J Am Coll Clin Pharm. 3(8):1493-1513. DOI: 10.1002/jac5.1331.

*Tran T, Ball J, Bratberg JP, DeSimone EM, Franko TS, Hill LG, Koh-Knox Sharp CP, Palombi L, Ventricelli D, Farrell D, Gandhi N, Moore T. (2020). Report of the 2020 special committee on substance use and pharmacy education. Am J Pharm Educ. 84(11):8421. DOI: 10.5688/ajpe8421.

*Litten K, Hill LG, Garza A, Srinivasa M. (2020). Increasing naloxone knowledge and use through direct-to-patient education. J Pharm Technol. 36(6):237-242. DOI: 10.1177/8755122520954218.

*Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG. (2020). Opioid-related education provided by continuing education divisions at US pharmacy schools. Am J Pharm Educ. 84(10):8001. DOI: 10.5688/ajpe8001.

*Renfro ML, Loera LJ, Tirado CF, Hill LG. (2020). Lofexidine for acute opioid withdrawal: A clinical case series. Ment Health Clin. 10(5):259-263. DOI: 10.9740/mhc.2020.09.259.

*Zagorski CM, Myslinski JM, Hill LG. (2020). Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective. Int J Drug Policy. 86:102939. DOI: 10.1016/j.drugpo.2020.102939.

*Hill LG, Evoy KE, Reveles KR. (2020). Reply to a letter regarding, “Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction”. J Am Pharm Assoc. 60(5):e22-23. DOI: 10.1016/j.japh.2020.02.019.

*Mackert M, Pounders K, Brown L, Kirtz S, Hughes Wagner J, Ring D, Hill LG, Wilcox G, Murthy D, Tierney W, Innerarity S, McGlone M, Holleran Steiker LK, DeSalvo K, Bernhardt J, Pretorius K. (2020). Development of a health communication campaign to promote the Texas prescription monitoring program. Health Mark Q. 37(3):222-231. DOI: 10.1080/07359683.2020.1802967.

*Peterson J, Barner J, Lai P, Garza A, Hinds A, Nguyen M, Hill LG, Gums T. (2020). Impact of physician-pharmacist covisits at a primary care clinic in patients with uncontrolled diabetes. J Pharm Pract. 33(3):321-325. DOI: 10.1177/0897190018807374.

*Hill LG, Holleran Steiker LK, Mazin L, Kinzly ML. (2020). Implementation of a collaborative model for opioid overdose prevention on campus. J Am Coll Health. 68(3):223-226. DOI: 10.1080/07448481.2018.1549049.

*Evoy KE, Groff L, Hill LG, Godinez W, Gandhi R, Reveles KR. (2020). Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. J Am Pharm Assoc. 60:81-86. DOI: 10.1016/j.japh.2019.09.007.

*Hill LG, Laguado SA. (2019). Guidance for male mentors to support the safety and success of female mentees. Am J Pharm Educ. 83(10):7533. DOI: 10.5688/ajpe7533.

*Hill LG, Evoy KE, Reveles KR. (2019). Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. J Am Pharm Assoc. 59(6):779-782. DOI: 10.1016/j.japh.2019.06.019.

*Hill LG, Reveles KR, Evoy KE. (2019). State-level approaches to expanding pharmacists’ authority to dispense naloxone may affect accessibility. JAMA Intern Med. 179(10):1442-1443. DOI: 10.1001/jamainternmed.2019.3653.

*Evoy KE, Hill LG, Groff L, Mazin L, Carlson CC, Reveles KR. (2018). Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. JAMA. 320(18):1934-1937. DOI: 10.1001/jama.2018.15892.

*Hill LG, Sanchez JP, Laguado SA, Lawson KA. (2018). Operation Naloxone: Overdose prevention service learning for student pharmacists. Curr Pharm Teach Learn. 10(10):1348-1353. DOI: 10.1016/j.cptl.2018.07.010.

*Murphy JE, Liles AM, Bingham AL, Chamberlin K, Dang D, Hill LG, Lee M, Leonard A, Lodise N, Rogers E. (2018). Interprofessional education: Principles and application. An update from the American College of Clinical Pharmacy. J Am Coll Clin Pharm. 1:e17-28. DOI: 10.1002/jac5.1025.

*Jordan RP, Bratberg J, Congdon HB, Cross LB, Hill LG, Marrs JC, McBane S, Lang WG, Ekoma JO. (2017). The report of the 2016-2017 advocacy standing committee. Am J Pharm Educ. 81(8):S10. DOI: 10.5688/ajpeS10.

*Han JK, Hill LG, Koenig ME, Das N. (2017). Naloxone counseling for harm reduction and patient engagement. Fam Med. 49(9):730-733.

*Corbo JM, DeLellis TM, Hill LG, Rindfuss SL. (2016). ACE inhibitors or ARBs to prevent CKD in patients with microalbuminuria. Am Fam Physician. 94(8).652-653.

*Hill LG, Chee JS, Haugh AJ, Wilson SA. (2015). Does time of day affect lipoprotein measurement independent of fasting state? Evidence-Based Practice. 18(7):11. DOI: 10.1097/01.EBP.0000541014.38985.c7.

*Hill LG, Dupuis KM. (2015). Compounded vancomycin solution for Clostridium difficile infection. Evidence-Based Practice. 18(7):2. DOI: 10.1097/01.EBP.0000541002.47570.d0.

*Hill LG. Lorcaserin and phentermine/topiramate: Two leaps forward in weight loss pharmacotherapy. (2013). Ann Pharmacother. 47(12):1740. DOI: 10.1177/1060028013513557.